Wildcatters welcome: The need for new antimicrobial agents

Therapy

Volumn 1, Issue 1, 2004, Pages 1-5

  Ray, Amy ^a   Rice, Louis B ^a  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; ARESTIN; CEFTRIAXONE; CEPHALOSPORIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GARENOXACIN; GLYCOPEPTIDE; GLYCYLCYCLINE DERIVATIVE; KETOLIDE; LINEZOLID; METICILLIN; MINOCYCLINE; NATURAL PRODUCT; ORITAVANCIN; PENICILLIN G; POLIOMYELITIS VACCINE; PRISTINAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAMOPLANIN; SMALLPOX VACCINE; TELITHROMYCIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTHRALGIA; BACTERIAL GENOME; CLINICAL TRIAL; DRUG DESIGN; DRUG HALF LIFE; DRUG INDUSTRY; DRUG TARGETING; ECONOMIC ASPECT; EDITORIAL; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEALTH CARE SYSTEM; HUMAN; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUSCLE INJURY; MYALGIA; PENICILLIN RESISTANCE; PHLEBITIS; POINT MUTATION; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; THROMBOCYTOPENIA; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 12844285918     PISSN: 14750708     EISSN: None     Source Type: Journal    
DOI: 10.1586/14750708.1.1.1     Document Type: Editorial

References (23)

1. Wilson JF. Renewing the fight against bacteria. The Scientist 16, 22 (2002).
2. Clarke T. Drug companies snub antibiotics as pipeline threatens to run dry. Nature 425, 225 (2003).
3. Jacoby GA, Medeiros AA. More extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 35, 1697-1704 (1991).
4. Wise R, Andrews JM, Ashby J. In vitro activities of peptide deformylase inhibitors against Gram-positive pathogens. Antimicrob. Agents Chemother. 46, 1117-1118 (2002).
5. Sahm DF, Marsilio MY, Piazza G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with The Surveillance Network Database-USA. Clin. Infect. Dis. 29, 259-263 (1999).
6. Vergis EN, Hayden MY, Chow JW et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study. Ann. Intern. Med. 135, 484-492 (2001).
7. Shinabarger DL, Marotti KR, Murray RW et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob. Agents Chemother. 41, 2132-2136 (1997).
8. Gerson SL, Kaplan SL, Bruss JB et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob. Agents Chemother. 46, 2723-2726 (2002).
9. Marshall SH, Donskey CJ, Hutton-Thomas R, Salata RA, Rice LB. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob. Agents Chemother. 46, 3334-3336 (2002).
10. Lobritz M, Hutton-Thomas R, Marshall S, Rice LB. Recombination proficiency influences frequency and locus of mutational resistance to Linezolid in Enterococcus faecalis. Antimicrob. Agents Chemother. 47, 3318-3320 (2003).
11. Stratton CW, Liu C, Ratner HB, Weeks LS. Bactericidal activity of daptomycin (LY-146032) compared with those of ciprofloxacin, vancomycin and ampicillin against enterococci as determined by kill-kinetic studies. Antimicrob. Agents Chemother. 31, 1014-1016 (1987).
12. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 2538-2544 (2003).
13. Wasilewski MM, Disch DP, McGill JM et al. Equivalence of shorter course therapy with oritavancin vs. vancomycin/cephalexin in complicated skin/skin structure infections. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2001).
14. Seltzer E, Dorr MB, Goldstein BP et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis. 37, 1298-1303 (2003).
15. Wong MT, Kauffman CA, Standiford HC et al. Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin. Infect. Dis. 33, 1476-1482 (2001).
16. Biavasco F, Manso E, Varaldo PE. In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile. Antimicrob. Agents Chemother. 35, 195-197 (1991).
17. Zhanel GG, Hisanaga T, Nichol K, Wierzbowski A, Hoban DJ. Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae. Expert Opin. Emerg. Drugs 8, 297-321 (2003).
18. Fogarty CM, Kohno S, Buchanan P, Aubier M, Baz M. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin. J. Antimicrob. Chemother. 51, 947-955 (2003).
19. Fung-Tomc JC, Minassian B, Kolek B et al. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob. Agents Chemother. 44, 3351-3356 (2000).
20. Zhanel GG, Homenuik & Nichol K et al. The glycylgclines: a comparative review with the tetracyclines. Drugs 64, 63-88 (2004).
21. Visalli MA, Murphy E, Projan SJ, Bradford PA. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteins mirabilis. Antimicrob. Agents Chemother. 47, 665-669 (2003).
22. Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob. Agents. Chemother. 47, 972-978 (2003).
23. Henwood CJ, Gatward T, Warner M et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK and in vitro evaluation of tigecycline (GAR-936). J. Antimicrob. Chemother. 49, 479-487 (2002).